Joseph P. Lucia & Associates LLC reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 97.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 452 shares of the biopharmaceutical company’s stock after selling 19,896 shares during the period. Joseph P. Lucia & Associates LLC’s holdings in Gilead Sciences were worth $31,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Creative Financial Designs Inc. ADV grew its holdings in shares of Gilead Sciences by 55.9% during the first quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 165 shares during the last quarter. Trustcore Financial Services LLC purchased a new position in Gilead Sciences during the first quarter worth about $34,000. Weaver Consulting Group purchased a new position in Gilead Sciences during the first quarter worth about $34,000. Legacy Advisors LLC purchased a new position in Gilead Sciences during the second quarter worth about $37,000. Finally, Founders Capital Management boosted its holdings in Gilead Sciences by 50.0% during the first quarter. Founders Capital Management now owns 600 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 200 shares during the last quarter. 78.85% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ GILD traded down $0.69 during midday trading on Wednesday, hitting $66.40. The company’s stock had a trading volume of 4,182,545 shares, compared to its average volume of 5,225,046. The company’s fifty day simple moving average is $67.29. Gilead Sciences, Inc. has a one year low of $60.32 and a one year high of $79.61. The company has a quick ratio of 3.53, a current ratio of 3.62 and a debt-to-equity ratio of 1.09. The stock has a market cap of $85.32 billion, a price-to-earnings ratio of 10.80, a price-to-earnings-growth ratio of 4.05 and a beta of 1.12.
Several research firms recently weighed in on GILD. BidaskClub upgraded shares of Zai Lab from a “sell” rating to a “hold” rating in a report on Wednesday, June 5th. Maxim Group set a $84.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Monday, July 15th. Mizuho set a $88.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Monday, July 15th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Monday, July 15th. Finally, Sanford C. Bernstein began coverage on shares of Gilead Sciences in a report on Friday, April 26th. They set an “outperform” rating and a $82.00 price target on the stock. Two research analysts have rated the stock with a sell rating, six have given a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $81.47.
In related news, EVP Brett A. Pletcher sold 5,816 shares of the company’s stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $68.75, for a total transaction of $399,850.00. Following the sale, the executive vice president now owns 27,198 shares of the company’s stock, valued at approximately $1,869,862.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Brett A. Pletcher sold 7,200 shares of the company’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $65.07, for a total transaction of $468,504.00. Following the sale, the executive vice president now directly owns 34,398 shares in the company, valued at approximately $2,238,277.86. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Recommended Story: Fibonacci Channel
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.